接受一线化疗免疫疗法的老年滤泡性淋巴瘤患者的生存率。 - Suppr

Suppr

超能文献

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.

作者信息

Griffiths Robert, Gleeson Michelle, Reyes Carolina, Knopf Kevin, Danese Mark

出版信息

Am J Hematol. 2010 Dec;85(12):963-7. doi: 10.1002/ajh.21878.

DOI:10.1002/ajh.21878

PMID:20981680

Abstract

摘要

相似文献

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.

Am J Hematol. 2010 Dec;85(12):963-7. doi: 10.1002/ajh.21878.

New treatment options have changed the survival of patients with follicular lymphoma.

J Clin Oncol. 2005 Nov 20;23(33):8447-52. doi: 10.1200/JCO.2005.03.1674. Epub 2005 Oct 17.

Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Leuk Res. 2013 Oct;37(10):1208-12. doi: 10.1016/j.leukres.2013.07.015. Epub 2013 Aug 5.

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.

Cancer. 2006 Sep 1;107(5):1014-22. doi: 10.1002/cncr.22093.

Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?

Oncology (Williston Park). 2018 Aug 15;32(8):404, 407-9.

Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.

Pediatr Blood Cancer. 2011 Aug;57(2):317-20. doi: 10.1002/pbc.23110. Epub 2011 Apr 1.

Comparative effectiveness of treatments for newly diagnosed follicular non-Hodgkin lymphoma.

Leuk Lymphoma. 2015;56(9):2728-30. doi: 10.3109/10428194.2015.1006219. Epub 2015 Mar 11.

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.

J Clin Oncol. 2003 Jun 1;21(11):2115-22. doi: 10.1200/JCO.2003.07.111.

What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?

Cancer J. 2012 Sep-Oct;18(5):383-9. doi: 10.1097/PPO.0b013e31826aed6d.

Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?

Lancet Haematol. 2018 Sep;5(9):e381-e382. doi: 10.1016/S2352-3026(18)30138-8.

引用本文的文献

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.

Blood Adv. 2021 Mar 23;5(6):1737-1745. doi: 10.1182/bloodadvances.2020002724.

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.

Med Care. 2016 Apr;54(4):343-9. doi: 10.1097/MLR.0000000000000486.

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

J Cancer Epidemiol. 2012;2012:978391. doi: 10.1155/2012/978391. Epub 2012 Aug 27.

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.

Blood. 2011 Nov 3;118(18):4808-16. doi: 10.1182/blood-2011-04-348367. Epub 2011 Aug 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验